Journal of Infection
Volume 60, Issue 3 , Pages 248-251 , March 2010

In vitro drug susceptibility of Mycobacterium bovis BCG Connaught and Tokyo strains

,Accepted 7 January 2010.

References 

  1. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353:1689–1694
  2. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;61:299–305
  3. Lamm DL. Efficacy and safety of bacille Calmette–Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31(Suppl. 3):S86–S90
  4. Grange JM. Complications of bacille Calmette–Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health. 1998;1:84–88
  5. Nadasy KA, Patel RS, Emmett M, Murillo RA, Tribble MA, Black RD, et al. Four cases of disseminated Mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma. South Med J. 2008;101:91–95
  6. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol. 1995;27(Suppl. 1):2–8
  7. Akaza H, Koiso K, Ozono S, Kuroda M, Kameyama T, Okajima E, et al. A clinical study of PMCJ-9 (Bacillus Calmette–Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol. 2003;33:382–390
  8. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette–Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008;15:309–313
  9. Yajko DM, Madej JJ, Lancaster MV, Sanders CA, Cawthon VL, Gee B, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol. 1995;33:2324–2327
  10. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol. 1998;36:362–366
  11. National Committee for Clinical Laboratory Standards . Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Approved standard (M24-A) Wayne, PA, USA: National Committee for Clinical Laboratory Standards; 2003;p. 1–60
  12. Japanese Association for Tuberculosis . The standard methods for bacterial diagnosis of tubercle bacillus. Tokyo, Japan: Japan Antituberculosis Association; 2007;p. 95–122
  13. Kwon HH, Tomioka H, Saito H. Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tuber Lung Dis. 1995;76:141–148
  14. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry. 2007;46:11998–12004
  15. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, Blanchard JS. Meropenem–clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009;323:1215–1218
  16. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53:316–318
  17. Shishido Y, Mitarai S, Otomo K, Seki M, Sato A, Yano I, et al. Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain. Int J Tuberc Lung Dis. 2007;11:1334–1338

PII: S0163-4453(10)00006-X

doi: 10.1016/j.jinf.2010.01.002

Journal of Infection
Volume 60, Issue 3 , Pages 248-251 , March 2010

Article Tools